Avinger Invests In Trials Of Lumivascular Peripheral Atherectomy Device As Company Restructures
Executive Summary
US FDA-approval for an in-stent restenosis trial of Avinger's Pantheris atherectomy system comes on the heels of positive results from the VISION trial of the Pantheris in patients with peripheral arterial disease of the lower extremities. Meanwhile, the company is restructuring to cut its expenses by half as its stock has been stuck below a dollar a share since April.
You may also be interested in...
Avinger: Finally, Seeing Through Total Occlusions, But Will Clinical Value Generate Economic Return?
Noted physician/entrepreneur John Simpson is back. His latest company, Avinger, has finally achieved his long-sought goal: combining imaging and therapeutics in catheter technology for crossing CTOs. Will clinical innovation be enough to reward Avinger in an increasingly economically focused medtech world?
CMR Signs Deal With J&J To Bring Robots To Europe And South America
CMR Surgical will collaborate with Johnson & Johnson/Ethicon to expand access to its Versius robotic surgery system.
Cordis Looks To Regain Previous Innovation Edge With Drug-Eluting Balloons
Medtech Insight followed-up with Cordis CEO Shar Matin to talk about the company’s path forward as an innovative intervention company following the acquisition of MedAlliance.